Induction of potent antitumor immunity by in situ targeting of intratumoral DCs
J. Clin. Invest. Katsuyoshi Furumoto, et al. 113:774 doi:10.1172/JCI19762 [Go to this article.]

Figure 3
Systemic Flt3L treatment fails to induce regression of CT26 tumors. (A and B) Graphs show tumor growth and survival of mice inoculated with 2 × 10⁶ CT26 cells transduced with CCL20 or with a mock vector either alone or in addition to eight daily injections of Flt3L, from the first day of the tumor challenge (mock + Flt3L). The results shown are representative of two separate experiments. *P < 0.05 between CCL20 group and mock, and mock + Flt3L groups. In B, survival rate in CCL20 groups was statistically higher than mock + Flt3L group (P < 0.0001). (C) Tumors were isolated 9 days after tumor inoculation (1 day after the last Flt3L injection), and the percentage of DCs relative to total tumor cells was analyzed by flow cytometry. *P < 0.05 between CCL20- and Flt3L-treated groups.